AGGREGATED External reporting by CNBC. This page summarizes the publisher's feed entry; the full article is on www.cnbc.com.
A little-known biotech’s high-stakes cancer bet just paid off and its shares doubled
Genmab’s shares have doubled in three months after a string of cancer drug trial wins, strengthening its push to own more of the medicines it develops.